Fresenius stock slips 0.3 percent as strong half year meets risk

Published on 09/23/2026 at 12:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock traded at EUR 45.44 on September 23, 2026, down 0.3 percent. First-half revenue rose 7.3 percent to EUR 11.8 billion.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius SE and Co. KGaA (ISIN DE0005785604) traded at EUR 45.44 on Xetra on September 23, 2026, down 0.3 percent from the EUR 45.57 prior close. The stock remains 14.2 percent below its 52-week high of EUR 52.96, while its 52-week low is EUR 35.11.

Half-year growth remains measurable

According to Investing.com on September 23, 2026, Fresenius reported first-half revenue of EUR 11.8 billion, up 7.3 percent from the prior-year period. EBIT reached EUR 1.34 billion, an increase of 9.8 percent, with an EBIT margin of 11.4 percent.

The earnings quality also improved at the shareholder level. Net income attributable to shareholders rose 12.8 percent to EUR 530 million in the first half of 2026, according to Investing.com.

Analyst consensus stays above market

The gap between the share price and published valuation measures is substantial in absolute terms. The analyst consensus cited by Investing.com stood at Strong Buy from 14 analysts, with an average target of EUR 55.59 as of September 23, 2026. That target is EUR 10.15 above the Xetra price, a difference of 22.3 percent.

The principal counter-factor is operational risk at Fresenius Medical Care, the dialysis subsidiary. Investing.com reported on September 23, 2026, that a cybersecurity incident at FMC was a current headline factor, while operations were described as not materially affected. The development adds a specific execution and disruption risk to an otherwise improving half-year earnings profile.

Stock stays below the yearly high

Fresenius had a market capitalization of EUR 25.6 billion as of September 23, 2026. At EUR 45.44, the stock was EUR 7.52 below the 52-week high of EUR 52.96 and EUR 10.33 above the 52-week low of EUR 35.11, placing the current quote closer to the middle of its annual range than to either extreme.

For investors, the central numerical contrast is clear: first-half revenue grew 7.3 percent and EBIT grew 9.8 percent, while the share price was down 0.3 percent on September 23, 2026. The market valuation therefore reflects both stronger reported profitability and the risk attached to the wider healthcare group.

EUR 45.44 marks the reference quote

Fresenius stock stood at EUR 45.44 on Xetra as of September 23, 2026, compared with a prior close of EUR 45.57 and a daily change of minus 0.3 percent. The next balance-sheet date shown in the current market overview is November 4, 2026.